Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.

Vanderbilt biochemists have discovered what the DNA damage response protein RADX does — and how it does it.

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

A compound that increases lifespan in yeast is offering clues to pharmacological approaches that might slow the aging process and improve health.

Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.